MedTrace Logo

Tacrine Effects on Cocaine Self-Administration and Pharmacokinetics

NCT01406522 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-12-18

No results posted yet for this study

Summary

No medications are currently available for treatment of psychostimulant addiction, a compulsive preoccupation with use of cocaine and related compounds. Tacrine, a medication that is currently prescribed for Alzheimer's disease, can decrease the amount of cocaine injections that laboratory animals choose to inject by vein. This project will determine if tacrine can also decrease cocaine-motivated behavior for human subjects in a laboratory setting.

Conditions

  • Cocaine Dependence

Interventions

DRUG

Oral tacrine

Tacrine, 160 mg per day, four times daily

DRUG

Oral placebo

Microcrystalline cellulose

Sponsors & Collaborators

  • Midwest Biomedical Research Foundation

    lead OTHER

Principal Investigators

  • Kenneth W Grasing, M.D. · Kansas City VA Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2013-09-30
Completion
2013-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01406522 on ClinicalTrials.gov